Skip to content

A Study on the Efficacy and Hemodynamic Mechanisms of Atropine Combined with Flipper Training for Controlling Myopia Progression in Adolescents Based on Optical Coherence Tomography Angiography (OCTA)

A Study on the Efficacy and Hemodynamic Mechanisms of Atropine Combined with Flipper Training for Controlling Myopia Progression in Adolescents Based on Optical Coherence Tomography Angiography (OCTA)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126417
Enrollment
Unknown
Registered
2026-06-09
Start date
2026-06-09
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Control group (Group B):HAL spectacles + 0.01% atropine + placebo training
Intervention group (Group A):HAL spectacles + 0.01% atropine + Flipper accommodative training

Sponsors

Shenzhen Children’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1.Age 6–14 years (inclusive), any sex; 2.Spherical equivalent refraction (SER) between -1.00 D and -6.00 D in both eyes; 3.Astigmatism = 0.75 D in the past year; 5.Normal intraocular pressure and no family history of glaucoma; 6.Able to cooperate with all study examinations and Flipper training, and with informed consent signed by the guardian

Exclusion criteria

Exclusion criteria: 1.Any organic eye disease (e.g., strabismus, amblyopia, cataract, glaucoma, fundus lesions, etc.); 2.History of ocular trauma or ocular surgery; 3.Allergy to atropine or any component of its preparation; 4.Systemic diseases that may affect refractive development (e.g., diabetes mellitus, Marfan syndrome, etc.); 5.Use of atropine, orthokeratology, or other myopia control interventions within 3 months prior to enrollment; 6.Inability to comply with follow-up visits or complete home-based training

Design outcomes

Primary

MeasureTime frame
Axial length;

Secondary

MeasureTime frame
Adverse EventsAdverse Events (e.g., photophobia, allergy);Accommodative Facility;Subfoveal Choroidal Thickness;Spherical equivalent refraction;Fundus Examination;Intraocular Pressure;Choriocapillaris Flow Density;Superficial Retinal Vascular Density;Best-Corrected Visual Acuity;Accommodative Amplitude;Anterior Segment Examination;

Countries

China

Contacts

Public ContactXiaojuan Zhang

Shenzhen Children’s Hospital

13902946919@163.com+86 755 8288999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026